Login to Your Account

Santhera, Takeda Extend Pact For Idebenone In DMD

By Cormac Sheridan

Wednesday, August 8, 2007
Santhera Pharmaceuticals AG licensed European rights to idebenone in Duchenne muscular dystrophy (DMD) to Takeda Pharmaceutical Co. Ltd., in return for an up-front payment of €2 million, another €18 million (US$24.6 million) in milestones and royalties on eventual product sales. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription